Cargando…

Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups

OBJECTIVES: In the absence of large, prospective, placebo-controlled studies of longer duration, substantial evidence regarding the safety and risk of testosterone (T) therapy (TTh) with regard to cardiovascular (CV) outcomes can only be gleaned from observational studies. To date, there are limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Traish, Abdulmaged M., Haider, Ahmad, Haider, Karim Sultan, Doros, Gheorghe, Saad, Farid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555449/ https://www.ncbi.nlm.nih.gov/pubmed/28421834 http://dx.doi.org/10.1177/1074248417691136

Ejemplares similares

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study
por: Haider, Karim Sultan, et al.
Publicado: (2020)

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
por: Saad, Farid, et al.
Publicado: (2018)

Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years
por: Haider, Ahmad, et al.
Publicado: (2014)

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study
por: Traish, A M, et al.
Publicado: (2014)

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
por: Haider, Ahmad, et al.
Publicado: (2016)

SUN-222 Testosterone Treatment in Men with Classical vs. Functional Hypogonadism: A 9-Year Registry
por: Zitzmann, Michael, et al.
Publicado: (2019)

Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men
por: Saad, Farid, et al.
Publicado: (2015)

Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
por: Haider, Ahmad, et al.
Publicado: (2014)

Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study
por: Saad, F., et al.
Publicado: (2020)

Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2016)

Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies
por: Saad, F, et al.
Publicado: (2016)

Erratum: Correction of the references for Figures. Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2017)

Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy
por: Haider, Ahmad, et al.
Publicado: (2017)

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome
por: Traish, Abdulmaged M., et al.
Publicado: (2018)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

Testosterone and weight loss: the evidence
por: Traish, Abdulmaged M.
Publicado: (2014)

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
por: Yassin, AA, et al.
Publicado: (2013)

Recognizing the True Value of Testosterone Therapy in Health Care
por: Morgentaler, Abraham, et al.
Publicado: (2022)

Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer
por: Morgentaler, Abraham, et al.
Publicado: (2020)

Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data
por: Alwani, Mustafa, et al.
Publicado: (2021)

Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism
por: Almehmadi, Yousef, et al.
Publicado: (2016)

Testosterone Replacement Therapy and Bone Mineral Density in Men with Hypogonadism
por: Kim, Se Hwa
Publicado: (2014)

Cognitive effects of testosterone and finasteride administration in older hypogonadal men
por: Borst, Stephen E, et al.
Publicado: (2014)

Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men
por: Dadhich, Pranav, et al.
Publicado: (2017)

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
por: Ide, Veerle, et al.
Publicado: (2020)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence
por: Traish, Abdulmaged, et al.
Publicado: (2018)

FRI444 Testosterone Therapy in Men with Classical vs Functional Hypogonadism: Results from a Controlled 9-year, Real-world Registry Study
por: Zitzmann, Michael
Publicado: (2023)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
por: de Almeida Ferreira, Maurício, et al.
Publicado: (2022)

Testosterone replacement in male hypogonadism
por: Kalra, Sanjay, et al.
Publicado: (2010)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

Morning free and total testosterone in HIV-infected men: implications for the assessment of hypogonadism
por: Monroe, Anne K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2oa3vs8ujul6t24crdqkvhedmm